Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Non Operating Income (2016 - 2026)

Protara Therapeutics' Non Operating Income history spans 14 years, with the latest figure at $1.8 million for Q1 2026.

  • Quarterly Non Operating Income fell 16.43% to $1.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Mar 2026, up 12.23% year-over-year, with the annual reading at $7.1 million for FY2025, 55.99% up from the prior year.
  • Non Operating Income came in at $1.8 million for Q1 2026, up from $1.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.2 million in Q1 2025 to a low of $119000.0 in Q1 2022.
  • The 5-year median for Non Operating Income is $846000.0 (2023), against an average of $1.0 million.
  • Year-over-year, Non Operating Income soared 1560.0% in 2022 and then fell 16.43% in 2026.
  • Protara Therapeutics' Non Operating Income stood at $542000.0 in 2022, then surged by 51.29% to $820000.0 in 2023, then surged by 88.17% to $1.5 million in 2024, then increased by 14.84% to $1.8 million in 2025, then rose by 4.23% to $1.8 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Non Operating Income are $1.8 million (Q1 2026), $1.8 million (Q4 2025), and $1.5 million (Q3 2025).